Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 1,201–1,300 of 1,733
Kirby, M. G., Kalhan, A., & Hackett, G. I. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1773259 · Cited by 1
Male Hypogonadism: The Korean Society of Men's Health and Aging Position Statement
Ahn, S. T., Kim, Y., Yu, S. H., & Chung, Y. (2025) · The World Journal of Men s Health · doi:10.5534/wjmh.240266 · Cited by 1
“For instance, the BSSM and the EAU recommend this approach, while the ES takes a more conservative stance, advising against T therapy in men with a palpable prostate nodule, induration, or a PSA level ≥4 ng/mL [5,6,8].”
InfluentialNordenstrom, A., Ahmed, S. F., van den, A. E., Blair, J., Bonomi, M., Brachet, C., Broersen, L. H. A., der, G. H. C.-V., Dessens, A. B., Gawlik, A. M., et al. (2022) · Yearbook of pediatric endocrinology · doi:10.1530/ey.19.6.1 · Cited by 1
Jamalinia, M., Lonardo, A., & Weiskirchen, R. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70038 · Cited by 2
“Clinicians should follow established TRT guidelines for indications, dosing, and monitoring during therapy [54–56].”
Castle, G., & Stammers, J. G. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13448 · Cited by 1
Abichandani, V. K., & Kalhan, A. (2023) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_cdrp_20_22 · Cited by 1
Association of Testosterone With Lean Soft Tissue and Handgrip Strength Across Middle‐Aged Men
Prokopidis, K., Cacciatore, S., McLean, J., Piaggi, P., Prado, C. M., Batsis, J. A., & Schlögl, M. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70329 · Cited by 1
“There is no universal consensus among endocrinology and urology guidelines on the definition of testosterone deficiency, with deficiency cut-off values ranging from 230 to 346 ng/dL, depending on the specific guideline body [17], although normal levels range from 450 to 600 ng/dL [18].”
Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in Men
Canales, S. P., Iqbal, I., Akande, R. O., Ghimire, A., Kalishman, A. J., Wood, E. M., Albert, S. G., & Dhindsa, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.003 · Cited by 3
When Blood Remembers Its Sex: Toward Truly Personalized Transfusion Medicine
Fortis, S. P., Kokoris, S. I., Kelepousidis, P., Dryllis, G., Kosma, M.-A., Pittaras, T., Kriebardis, A. G., & Valsami, S. I. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120592 · Cited by 1
“…reveal additional differences: plasma from females contains higher levels of acute-phase proteins (e.g., haptoglobin), whereas the levels of coagulation factors (e.g., factor VIII) are reduced compared to male plasma, reflecting the influence of estrogens and testosterone, respectively [82–84].”
Frequency and Correlation of Hypogonadism in Men with Type 2 Diabetes
Ali, A., Naeem, A., Naseer, L., Naeem, N., Waheed, S., & Mastoor, M. (2022) · doi:10.53350/pjmhs221610393 · Cited by 1
Morgentaler, A., Lodaya, K. J., Telang, S., Hayashida, D. K., & Hu, Y. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0024 · Cited by 1
Varghese, J. M., & Best, C. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_4 · Cited by 1
Testosterone Therapy with a Man with Equivocal Testosterone Levels
Corona, G., & Maggi, M. (2022) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2022.03.601 · Cited by 2
Hyperprolactinemia in Men with Testosterone Deficiency
Trost, L. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-77111-9_4 · Cited by 1
Endocrine Complications of Chronic Kidney Disease
LaFave, L., Haselby, D., & Hart, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00034-6 · Cited by 1
Testosterone deficiency, the unrecognised consequence of the opioid epidemic in men
David, J., & Kirby, M. (2022) · Trends in Urology & Men s Health · doi:10.1002/tre.846 · Cited by 2
Rosen, S. H., & Asanad, K. (2025) · Medicines · doi:10.3390/medicines13010001 · Cited by 2
“For those who qualify, TTh aims to induce and maintain secondary sex characteristics, correct symptoms of androgen deficiency, and ultimately improve patients’ quality of life [1,3].”
InfluentialEndocrine Manifestations of Alcohol and Other Drug Use Disorders
Quirk, A. R., & Twigg, S. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_84 · Cited by 2
Gonadal Dysfunction in Wolfram Syndrome: A Prospective Study
Esteban-Bueno, G., & Fernández‐Martínez, J. L. (2025) · Diagnostics · doi:10.3390/diagnostics15131594 · Cited by 4
Yassin, A. A. (2022) · Current Trends in Internal Medicine · doi:10.29011/2638-003x.100061 · Cited by 1
“dose reduction or therapeutic phlebotomy) [11-15].”
Testosterone and Cardiovascular Effects
Yeap, B. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_19 · Cited by 1
Dajani, A.-H. J., Liu, T. P., Araujo-Espinoza, G., Muy, K. B., Cope, S., Jones, K. J., & Kremen, T. J. (2026) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671261430731 · Cited by 1
“3 In women, TRT is primarily used for treatment of hypoactive sexual desire disorder and is given at much lower doses 4,21 to approximate physiological premenopausal levels.”
Methods of correction of hypogonadism syndrome in men and long-term results of drug treatment
Романовна, Р. Е., Rozhivanov, R. V., Морозова, Е. В., Gaidaichuk, K. E., Mel'nichenko, G. A., Andreeva, E. N., & Mokrysheva, N. G. (2025) · Bulletin of Reproductive Health · doi:10.14341/brh12770 · Cited by 1
High-fidelity reprogramming into Leydig-like cells by CRISPR activation and paracrine factors
Li, Z., Fan, Y., Xie, C., Liu, J., Guan, X., Li, S., Huang, Y., Zeng, R., Chen, H., & Su, Z. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac179 · Cited by 1
“However, testosterone therapy is far from a perfect solution due to its potential adverse effects, such as reduced sperm production and fertility, promoting metastatic prostate cancer growth, and erythrocytosis (10).”
Vierbaum, L., Kaiser, P., Keller, T., Weber, S., Schellenberg, I., Luppa, P. B., Wenzel, F., & Thevis, M. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1758376 · Cited by 1
Assessment of Cardiovascular Risk for Noncardiac and Nonsurgical Activities
Perry, C., Budweg, J. B., Stein, A. P., Harder, J., Gupta, S. K., Nusbickel, A. J., Smoot, M., Patel, K., & Winchester, D. E. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.12.003 · Cited by 1
STOBBE, P. R., Tatit, U. L., Guedes, M. H., Baena, C. P., & Rech, C. M. Z. (2024) · Revista Caribeña de Ciencias Sociales · doi:10.55905/rcssv13n4-013 · Cited by 2
Sertoli cells-only syndrome: current clinical approaches and ongoing research trends
Eugeni, E., Arato, I., Mancuso, F., Brancorsini, S., Luca, G., & Köfler, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1715642 · Cited by 10
“In patients with concomitant Leydig cell dysfunction and hypergonadotropic hypogonadism, testosterone replacement therapy should be considered based on the clinical situation, age and desire to have children (93).”
Metabolic and endocrine diseases - is our approach always rational?
Brunerová, L., Urbanová, J., & Brož, J. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.107 · Cited by 1
Oğuz, S. H., & Yıldız, B. O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98804-9.00029-3 · Cited by 1
Nosologie andrologischer Krankheitsbilder
Nieschlag, E., Tüttelmann, F., Kliesch, S., & Behre, H. M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-61901-8_4 · Cited by 1
Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes
Ruggiero, C., Caffarelli, C., Calsolaro, V., Tafaro, L., Riuzzi, F., Bubba, V., Napoli, N., Ferracci, M., Mecocci, P., Giusti, A., et al. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01163-4 · Cited by 1
“Diagnosing hypo-gonadism requires two early morning (preferably fasting) testosterone measurements [76].”
The Relationship Between Low Testosterone Levels and Asthenia in Adult Patients: An Original Study
Iftikhar, M., Khan, I., Jamal, A., & Khan, S. J. (2024) · Journal of Postgraduate Medical Institute · doi:10.54079/jpmi.38.4.3488
Simón-Silva, P., Acuña, R. D. C., Bejarano, J. S., Sanchez-Galvez, A., Lazo, A., & Blanco-Villar, M. L. (2025) · Therapeutics · doi:10.3390/therapeutics2040016 · Cited by 1
“Androgens, primarily testosterone and its derivative dihydrotestosterone (DHT), are male sex hormones that play a fundamental role in the development and maintenance of male sexual characteristics, as well as in the regulation of prostate growth [8,9].”
Longitudinal Changes in Sex Hormones in a Population of Older Community-dwelling Men
Hills, S. T., Mansfield, T. A., Bhasin, S., & ORWOLL, E. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf652 · Cited by 2
Self-citationTestosteron – „Benzin“ für den alten Mann?
Zitzmann, M. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01824-x · Cited by 3
Anabolic and anticatabolic agents in kidney disease and kidney failure
Chiang, J. M., & Johansen, K. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00040-9 · Cited by 1
Tienforti, D., Terrana, G., Geronimo, R. D., Perfetto, E., Spagnolo, L., Baroni, M. G., & Barbonetti, A. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02945-w · Cited by 2
Stangl, T. A., Wiepjes, C. M., Heijboer, A. C., & den Heijer, M. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120429 · Cited by 2
Exogenous Testosterone Causes Delayed Postnatal Testicular Development and Disrupts Spermatogenesis
Gofur, M. R., Khatun, A., Sa'di, M., Aktar, S., & Alam, M. E. (2023) · Journal of Science and Technology Research · doi:10.3329/jscitr.v4i1.67366 · Cited by 3
“Intratesticular testosterone levels and total testosterone production, therefore, decline (Bhasin et al., 2018; Crosnoe et al., 2013).”
BackgroundSadh, P., Warzecha, H., Dassow, M., Lewis, A. M., Peresuh, S. J., Carayannopoulos, N. L., Gandhi, S. D., Daniels, A. H., & Basques, B. A. (2026) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2026.112088 · Cited by 1
Erectile Dysfunction: A Primer for in Office Management
Sami, S., Stern, N., Pierdomenico, A. D., Katz, B. G., & Brock, G. B. (2019) · Medical Sciences · doi:10.3390/medsci7090090 · Cited by 2
“These values align with the lower limit of normal of most testosterone assays and the cut-off for hypogonadism in many clinical guidelines [58].”
BackgroundIncidence, Temporal Trends, and Socioeconomic Aspects of Acquired Male Hypogonadism
Percik, R., Vered, S., & Liel, Y. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2556-2844 · Cited by 2
“Compensated hypogonadism refers to a “subclinical” type of testicular failure requiring higher LH to maintain “normal” concentrations of testosterone [4, 5].”
Burte, C. (2022) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2022.03.001 · Cited by 1
Sex hormones, related compounds and hormonal contraceptives including miscellaneous hormones
Tatachar, A., & Gibson, C. M. (2019) · Side effects of drugs annual · doi:10.1016/bs.seda.2019.06.003 · Cited by 1
Неспецифический реактивный гепатит у больных желчнокаменной болезнью
Бычков, С. А. (2007) · Electronic Kharkiv National University Institutional Repository (Kharkiv National University)
(2000) · Time to knit · doi:10.1016/s1155-1941(23)43256-8
Hormonal Laboratory Examination
Fanelli, F., D’Aurizio, F., Brunetti, A., Spaggiari, G., Pagotto, U., & Granata, A. R. M. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_16-2
Muñoz-López, M., Quesada-Fernández, G., Sancho-Haro, E. S., Viúdez, X. R. D. L. P., Baz-Valle, E., López‐Gil, J. F., & Tornero-Aguilera, J. F. (2026) · Metabolites · doi:10.3390/metabo16070483 · Cited by 1
Winning streaks in teams and the role of testosterone: Evidence from professional tennis data
Ferguson, N. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.245031
Gagliano‐Jucá, T., Puri, I., Ramirez-Rivera, G., Shekhar, S., Valderrábano, R. J., Goldman, A. L., Beleva, Y. M., Weiss, M., Shang, Y. V., Pencina, K. M., et al. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag185
“Notably, all met predefined criteria for primary hypogonadism (1).”
Self-citationMcLean, A., Hoq, M., Pang, K. C., & O’Connell, M. A. (2025) · Transgender Health · doi:10.1089/trgh.2024.0233
Gewichtstoename en overgewicht
Huls, M. H. J., Boon, M. R., & van Rossum, E. F. C. (2026) · doi:10.1007/978-90-368-3158-1_9
WHOLE PLANT ADIANTUM CAPILLUS-VENERIS LINN. EXTRACT AS AN ANTI-COVID-19 THERAPY.Preprint
Hendawy, L. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/4cke7
Comment diagnostique-t-on un hypogonadisme ?
Huyghe, É. (2024) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2023.10.006
Clift, A. K., Johnson, H. H., Huang, D. R., & Morgentaler, A. (2025) · The World Journal of Men s Health · doi:10.5534/wjmh.250245 · Cited by 1
Testosterone and Cardiovascular Disease: The Enduring Myth
Mauvais‐Jarvis, F. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf629 · Cited by 1
Endocrinological Aspects of Sarcopenia
Minnetti, M., Poggiogalle, E., Vincenzo, O. D., Migliaccio, S., & Donini, L. M. (2026) · Endocrinology · doi:10.1007/978-3-030-71067-5_22-1
Taylor, S. R. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.malehypogonadism_overview
Nabid, A., Carrier, N., Vigneault, É., Martin, A., Nguyen, T. V., Bahary, J.-P., Vavassis, P., Bahoric, B., Brassard, M.-A., Archambault, R., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.09.062 · Cited by 1
Counselling for Testosterone Therapy in Mid Life Men
Kalra, S., Joshi, A. S., Dhingra, A., Dutta, D., & Das, S. (2022) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_240_20 · Cited by 1
“Though universal screening for testosterone deficiency is not recommended, assessment of testosterone adequacy should be done if symptoms, signs, or surrogate laboratory markers are suggestive.[7,8] While monitoring is ideally done by measuring testosterone levels at appropriate intervals, it should be supplemented wi…”
BackgroundOk, P. G., Yılmaz, N., & Demir, O. (2026) · Neurological Research · doi:10.1080/01616412.2026.2636854
Anawalt, B. D. (2022) · doi:10.1093/med/9780198870197.003.0482
Moderne Vorsorge beim Mann: Schnittstellen zwischen GrundversorgerInnen und FachärztInnen
Würnschimmel, C., Bütikofer, S., & Zahiti, L. (2025) · Urologie in der Praxis · doi:10.1007/s41973-025-00312-5
An Interesting Case of Hypogonadism: Workup in a Phenotypic Male Reveals XX Genotype
Sharma, T., & Mehta, A. J. (2022) · JCEM Case Reports · doi:10.1210/jcemcr/luac033
“• The first step in managing men with confirmed hypo-gonadism is to differentiate between primary vs secondary (8) causes based on clinical presentation and blood work.”
BackgroundPathogenetic and diagnostic features of osteoporosis in men
Холманских, А. С., & Lesnyak, O. M. (2025) · Russian Family Doctor · doi:10.17816/rfd697563
Johnson, H. J. (2026) · doi:10.21019/9781582123875.ch26
Morant, E. T., Puchol, O. R., Torres, S. G., et al. (2026) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2026.501799
Research progress of insulin-like peptide 3 in bone metabolismPreprint
Zhou, M., Liu, Y., Ji, C., Liang, J., Zhang, B., Wang, L., & Yang, X. (2024) · Authorea · doi:10.22541/au.172201688.89826604/v1
Chapter 43: Dermatologic Disorders
Ballou, J. M. (2026) · doi:10.21019/9781582123875.ch43
Dhindsa, S. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch85
Rizal, D. M., & Septiyorini, N. (2022) · Jurnal kedokteran dan kesehatan Indonesia · doi:10.20885/jkki.vol13.iss2.art14
Chapter 7: Clinical Pharmacokinetics
Laizure, S. C. (2026) · doi:10.21019/9781582123875.ch7
Peres, A. S. S., Peres, C. S., Saldanha, C. T., et al. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n3-013
(2026) · doi:10.21019/9781582123875.ind
Kamińska, M., Strzoda, A. J., & Polak, A. (2023) · Journal of Health Study and Medicine · doi:10.2478/jhsm-2023-0018
Broul, M., Radovnická, L., Schraml, J., Hlavička, M., Falion, M., Cihlář, F., & Zámečník, L. (2023) · Česká urologie · doi:10.48095/cccu2023015
Moseley, M. (2022) · The American Pharmacists Association eBooks · doi:10.21019/9781582123615.ch39
Ichino, K., Okui, N., Ide, H., & Horie, S. (2026) · Cureus · doi:10.7759/cureus.103956
“TRT is not recommended when near-term fertility is desired, and treatment selection therefore involves decision constraints [10].”
InfluentialConsideration of Gender on Hormone Therapy Management
Morgan, L. L. (2023) · Nursing Clinics of North America · doi:10.1016/j.cnur.2023.06.006
Finks, S. W. (2026) · doi:10.21019/9781582123875.ch16
Vignera, S. L., & Condorelli, R. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081321
“Observational Studies (Cohort, Case–Control, Cross-Sectional): The Newcastle– Ottawa Scale (NOS) [27] was used to assess quality across three domains: Selection (0–4 stars), Comparability (0–2 stars), and Outcome/Exposure (0–3 stars).”
Cleland, N. R. W., Graves, C. E., Reade, L. M., Nokoff, N., O’Connell, R. P., & Fang, N. Z. (2025) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2025.09.008 · Cited by 1
Vauhkonen, P. K., Haukka, J. K., Vauhkonen, I., Lindroos, K. M., & Mäyränpää, M. I. (2025) · Sports Medicine - Open · doi:10.1186/s40798-025-00854-5
Testosterone and Disordered Sleep
Yuen, F., Chavoshan, B., Waqfi, D., & Liu, P. Y. (2021) · Springer eBooks · doi:10.1007/978-3-030-77111-9_5
Biernikiewicz, M., Stołyhwo-Gofron, M., Kuryłowicz, A., Sobieszczańska, M. I., Roźek-Piechura, K., Okrzymowska, P., Markiewicz, M., Gebala, J., Majchrowska, M., & Kałka, D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15082946
“The European Society of Endocrinology and the European Academy of Andrology [36,37] emphasize the central role of obesity in the development of hypogonadism.”
Hypogonadism in aging men: Impact of comorbidities, diagnosis and treatment
Ravelli, S. A., Maseroli, E., & Vignozzi, L. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109124
(2023) · Emerald Group Publishing Limited eBooks · doi:10.1108/978-1-83753-756-320231014
Utility and Limitations in Measuring Testosterone
Grossmann, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_4
Glaser, R. L. (2026) · Cureus · doi:10.7759/cureus.106377
“Current guidelines recommend restoring serum total testosterone to mid-normal ranges for young men while avoiding supraphysiologic levels, with monitoring of trough or mid-cycle values, hematocrit, and PSA [8-10].”
Retracted(2000) · Time to knit · doi:10.1016/j.ccol.2023.02.016
Chehadeh, C., Nayar, K. H., Alegre, D., Auerbach, M. H., & Rappaport, D. E. (2026) · JEM Reports · doi:10.1016/j.jemrpt.2026.100231
Sherwood, J. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-52215-5_48
Phan, L. N., Murphy, K. J., Pearce, K. L., Tran, C. D., & Tremellen, K. P. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14030029
“Therefore, no participants were considered to have HG (population range 6.90–36.1 nmol/L) [51].”
BackgroundInfluentialTestosterone abuse in Brazil: a growing public health challenge
Fregonesi, A., Nascimento, B., Soares, J. M., Latronico, A. C., Abdo, C. H. N., Sanvido, L. V., Nardozza, A., Fácio, F. N., de Bessa, J., Torres, L. O., et al. (2026) · Clinics · doi:10.1016/j.clinsp.2026.101036
“4 In the setting of supraphysiologic AAS abuse, this hematologic risk is likely to be amplified.”
InfluentialHormone replacement therapy in patients with a history of cancer
Левченко, Н. Е., Efremov, E. A., Владимировна, К. Е., Sidorenko, Y. S., Melnik, Y. I., & Koryakin, A. V. (2019) · Practical oncology · doi:10.31917/2004310
Tuomisto, A., Pinola, P., Pesonen, P., Franks, S., Martikainen, H. K., Tapanainen, J. S., Niinimäki, M. J., & Morin-Papunen, L. C. (2025) · Andrology · doi:10.1111/andr.70122 · Cited by 1
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.